Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Data as at: 27/03/2024
In
Objective
To achieve long-term capital growth by investing in biotechnology and other life sciences companies.
AIC sector
Management group
Schroder Investment Management
Company website
Launch date
06/05/1994
August
Domicile
United Kingdom
Fund manager
Ailsa Craig, Marek Poszepczynski
Dividend frequency
Semi-Annually
Wind-up provisions
The Association Articles of the company provide for Directors to put forward a proposal for the continuation of the company at the AGM at two-yearly intervals. The upcoming continuation vote is scheduled for the December 2025 AGM.
Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
---|---|---|---|---|---|---|---|---|
248.73 | 309.14 | 654.00 | 739.97 | -11.62 | 6 | 4.31 | Jul, Dec | 1.4 (31/08/2023) |
Scroll
Dividends
Dividends declared in last 12 months
Ex-Dividend date | Payment date | Dividend amount | Special dividend | Financial year |
---|---|---|---|---|
21/12/2023 | 26/01/2024 | 13.900 | No | 2024 |
27/07/2023 | 25/08/2023 | 14.200 | No | 2023 |
Scroll
Performance (%)
Return type | 1 year | 3 years | 5 years | 10 years | |
---|---|---|---|---|---|
International Biotechnology | Share price total return | 4.4 | -0.1 | 28.8 | 220.7 |
Biotechnology & Healthcare AIC sector | Share price total return | 4.5 | -20.1 | 4.7 | 125.5 |
Scroll
Share structure
Number of shares
38,032,407
3,366,410
Traded volumes (number of shares)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 45,126 | 1,323,281 | 12,794,083 | 83,199,765 |
Average | N/A | 60,620 | 50,652 | 65,935 |
Scroll
Traded values (m)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 0.30 | 8.85 | 81.77 | 571.85 |
Average | N/A | 0.40 | 0.32 | 0.45 |
Scroll
Trading details
Top holdings
Data as at : 29/02/2024
Investment | % of total assets |
---|---|
Cytokinetics Inc | 5.2 |
Sv Fund Vi Investment | 4.8 |
Supernus Pharmaceuticals Inc | 4.6 |
Gilead Sciences Inc | 4.3 |
Biomarin Pharmaceutical Inc | 4.2 |
Vera Therapeutics Inc Class A | 4.2 |
United Therapeutics Corp | 3.9 |
Incyte Corp | 3.7 |
Amgen Inc | 3.5 |
Scb Sholo211123b 20-Feb-2024 6.4600% 20-Mar-2024 | -10.0 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.